Abstract |
In an attempt to evaluate an alternative drug treatment to benzodiazepines in generalized anxiety disorders, a placebo controlled trial was carried out with a new beta-adrenergic blocker (CPG 361 A). A low-dosage neuroleptic ( flupenthixol) was included as a reference drug. Depending on the clinical assessment scales the placebo treatment resulted in moderate to excellent improvement in 36% to 56% of the patients after four weeks of treatment. The active drugs generally had a higher improvement range (from 31% to 80%). The global improvement scale was found to be better than the other scales in discriminating between placebo (50% improvement) and the active drugs ( CGP 361 A brought about 78% improvement and flupenthixol brought about 80% improvement). However, only for flupenthixol was the difference of statistical significance.
|
Authors | H Bjerrum, P Allerup, K Thunedborg, K Jakobsen, P Bech |
Journal | Pharmacopsychiatry
(Pharmacopsychiatry)
Vol. 25
Issue 5
Pg. 229-32
(Sep 1992)
ISSN: 0176-3679 [Print] Germany |
PMID | 1357681
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adrenergic beta-Antagonists
- Anti-Anxiety Agents
- Propanolamines
- isamoltane
- Flupenthixol
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Adult
- Anti-Anxiety Agents
(therapeutic use)
- Anxiety Disorders
(drug therapy, psychology)
- Double-Blind Method
- Female
- Flupenthixol
(therapeutic use)
- Humans
- Male
- Middle Aged
- Propanolamines
(therapeutic use)
- Psychiatric Status Rating Scales
|